Global Ibuprofen API Market Size Study & Forecast, by Application (Headache, Arthritis, Other Applications), By End-user (CROs and CMOs, Pharmaceutical and Biopharmaceutical Companies), and Regional Analysis, 2023-2030

Global Ibuprofen API Market Size Study & Forecast, by Application (Headache, Arthritis, Other Applications), By End-user (CROs and CMOs, Pharmaceutical and Biopharmaceutical Companies), and Regional Analysis, 2023-2030

Global Ibuprofen API Market is valued approximately at USD XX billion in 2022 and is anticipated to grow with a growth rate of more than 4.8% over the forecast period 2023-2030. Ibuprofen API (Active Pharmaceutical Ingredient) is the pure, raw form of ibuprofen that is used to manufacture over-the-counter and prescription pain relievers and fever reducers. As a nonsteroidal anti-inflammatory drug (NSAID), ibuprofen helps in alleviating pain, reduce inflammation, and lower fever. Ibuprofen API undergoes stringent testing and quality control measures to ensure its safety, efficacy, and purity aligning with regulatory standards prior to its incorporation into pharmaceutical products. Ibuprofen API is an essential component of many formulations, including tablets, capsules, solutions and topical treatments, following it is produced. Ibuprofen API is used by pharmaceutical firms to make a variety of prescription and over-the-counter drugs that are designed to address various individual requirements experiencing pain, inflammation, and fever. The rapid evolution of Active Pharmaceutical Ingredients (APIs) in emerging economies, surge in pharmaceutical and biopharmaceutical production and the rapid expansion of geriatric demographic.

Additionally, the market is expected to be further propelled by the growing prevalence of chronic diseases such as rheumatoid arthritis, migraine, and musculoskeletal disorders. According to the World Health Organization article as of July 2022, musculoskeletal conditions affect nearly 1.71 billion individuals globally, making them a prominent contributor to disability on a worldwide scale. Among these conditions, low back pain recorded as the primary cause of disability in as many as 160 countries. Also, as per Statistics Canada's August 2022 report, arthritis affected 657,900 individuals aged 35 to 49, 2,042,100 individuals aged 50 to 64, and 3,138,500 individuals aged 65 and above in 2021. Thus, the rising incidences of musculoskeletal disorders among various age demographics worldwide is spurring the demand for pharmaceutical advancements and propelling the demand for ibuprofen as a preferred solution for pain relief. Moreover, the growing investment in the R&D activities, as well as the rise in demand for pain relief medications presents various lucrative opportunities over the forecast period. However, the adverse effects and safety concerns, along with the increasing regulatory scrutiny and compliance costs are hindering the market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Ibuprofen API Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 with largest market share owing to the rapid expansion of pharmaceutical industry, imposition of stringent regulatory approvals and quality standards, coupled with the increasing technological advancements in drug delivery. Whereas, Asia Pacific is expected to grow at the highest CAGR over the forecast years. The rising incidences of chronic diseases, growing healthcare expenditure, and population growth are significantly propelling the market demand across the region. Also, the region's market growth is significantly bolstered by strategic endeavors undertaken by key industry players, including the introduction of new products, collaborative ventures, and acquisitions. For instance, in September 2022, IOL Chemicals & Pharmaceuticals revealed plans to diversify its active pharmaceutical ingredient (API) and specialty chemicals portfolios, investing USD 36.1 million (INR 300 crore) to establish a plant in western India. With around 30% of its revenues derived from the commodity API ibuprofen, the new plant aims to double the company's sales within the next 5 years. Thus, these factors are anticipated to fuels the region's market share during the forecast period.


Major market players included in this report are:
BASF SE
Dr. Reddy's Laboratories Ltd
IOL Chemicals and Pharmaceuticals Limited
SI Group, Inc.
Sino-US Zibo Xinhua-Perrigo Pharmaceutical Co., Ltd
Solara Active Pharma Sciences Limited
Strides Pharma Science Limited
SX Pharma
Granules India Limited
Rochem International Inc.

Recent Developments in the Market:
 In July 2023, Granules India Limited decalred that the company’s Acetaminophen and Ibuprofen tablets received approval from the U.S. FDA. These tablets are indicated for the treatment of headaches, minor arthritis pain, toothaches, and other related conditions.
 In March 2022, Lonza announced the company has allocated a significant investment of USD 935 million to establish facilities in Portsmouth, New Hampshire, and Visp, Switzerland. Additionally, the company concluded a laboratory expansion initiative at its API manufacturing plant in Nansha, China, in August 2021.
 In November 2022, Solara Active Pharma Sciences Limited received approval from the European Directorate for the Quality of Medicines (EDQM) for its new multipurpose API manufacturing facility located in Vishakhapatnam, Andhra Pradesh. The approval specifically pertains to the manufacturing of ibuprofen API (Active Pharmaceutical Ingredient).

Global Ibuprofen API Market Report Scope:
 Historical Data – 2020 - 2021
 Base Year for Estimation – 2022
 Forecast period - 2023-2030
 Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
 Segments Covered - Application, End-user, Region
 Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:


By Application:
Headache
Arthritis
Other Applications

By End-user:
CROs and CMOs
Pharmaceutical and Biopharmaceutical Companies

By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Companies Mentioned
BASF SE
Dr. Reddy's Laboratories Ltd
IOL Chemicals and Pharmaceuticals Limited
SI Group, Inc.
Sino-US Zibo Xinhua-Perrigo Pharmaceutical Co., Ltd
Solara Active Pharma Sciences Limited
Strides Pharma Science Limited
SX Pharma
Granules India Limited
Rochem International Inc.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.